Dose increase of imatinib mesylate may overcome acquired resistance in bcr/abl-positive acute lymphoid leukaemia

被引：2
|
作者：
Piccaluga, PP
Malagola, M
Rondoni, M
Amabile, M
Paolini, S
Soverini, S
Gaitani, S
Visani, G
Baccarani, M
Martinelli, G
机构：
[1] Univ Bologna, Inst Haematol & Med Oncol L&A Seragnoli, Bologna, Italy
[2] S Salvatore Hosp, Dept Haematol, Pesaro, Italy
来源：
EUROPEAN JOURNAL OF HAEMATOLOGY | 2004年 / 72卷 / 04期
关键词：
D O I：
10.1111/j.1600-0609.2004.00212.x
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：302 / 303
页数：2
相关论文
共 47 条
  • [21] Safety and efficacy of STI-571 (imatinib mesylate) in patients with bcr/abl-positive chronic myelogenous leukemia (CML) after autologous peripheral blood stem cell transplantation (PBSCT)
    Fischer, T
    Reifenrath, C
    Hess, GR
    Corsetti, MT
    Kreil, S
    Beck, J
    Meinhardt, P
    Beltrami, G
    Schuch, B
    Gschaidmeier, H
    Hehlmann, R
    Hochhaus, A
    Carella, A
    Huber, C
    LEUKEMIA, 2002, 16 (07) : 1220 - 1228
  • [22] Pre-transplant imatinib-based therapy improves the outcome of allogeneic hematopoietic stem cell transplantation for BCR–ABL-positive acute lymphoblastic leukemia
    S Mizuta
    K Matsuo
    F Yagasaki
    T Yujiri
    Y Hatta
    Y Kimura
    Y Ueda
    H Kanamori
    N Usui
    H Akiyama
    Y Miyazaki
    S Ohtake
    Y Atsuta
    H Sakamaki
    K Kawa
    Y Morishima
    K Ohnishi
    T Naoe
    R Ohno
    Leukemia, 2011, 25 : 41 - 47
  • [23] Enhanced phosphorylation of Nbs1, a member of DNA repair/checkpoint complex Mre11-RAD50-Nbs1, can be targeted to increase the efficacy of imatinib mesylate against BCR/ABL-positive leukemia cells
    Rink, Lori
    Slupianek, Artur
    Stoklosa, Tomasz
    Nieborowska-Skorska, Margaret
    Urbanska, Katarzyna
    Seferynska, Ilona
    Reiss, Krzysztof
    Skorski, Tomasz
    BLOOD, 2007, 110 (02) : 651 - 660
  • [24] ANALYSIS OF GENOMIC BREAKPOINTS INDICATES THAT BCR-ABL IN ACUTE LYMPHOBLASTIC LEUKAEMIA MAY ARISE IN A COMMITTED LYMPHOID PROGENITOR CELL IN A SUBSET OF CASES
    Score, J. C.
    Calasanz, M. J.
    Pane, F.
    Ottmann, O.
    Yeh, R. -F
    Wiemels, J.
    Grand, F. H.
    Cross, N. C. P.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 : 428 - 428
  • [25] The achievement of molecular complete remission during treatment with imatinib mesylate correlates with relaspe free survival and overall survival in patients with ber/abl-positive acute lymphoblastic leukemia.
    Piccaluga, PP
    Malagola, M
    Amabile, M
    Bianchini, M
    Bosi, C
    Gaitani, S
    Giannini, B
    Isidori, A
    Pane, F
    Paolini, S
    Rondoni, M
    Russo, D
    Soverini, S
    Vigna, E
    Visani, G
    Martinelli, G
    Baccarani, M
    BLOOD, 2003, 102 (11) : 870A - 870A
  • [26] Inhibition of phosphotyrosine phosphatase-1B (PTP1B) induces resistance to the ABL kinase inhibitor imatinib mesylate (Gleevec®) in BCR-ABL positive leukemic cells.
    Koyama, N
    Koschmieder, S
    Tyagi, S
    Myloch, S
    Nuernberger, H
    Rossmanith, T
    Hofmann, WK
    Hoelzer, D
    Ottmann, OG
    BLOOD, 2004, 104 (11) : 576A - 577A
  • [27] The use of Imatinib resistance mutation analysis to direct therapy in Philadelphia chromosome/BCR-ABL1 positive chronic myeloid leukaemia patients failing Imatinib treatment, in Patan Hospital, Nepal
    Kayastha, Gyan K.
    Ranjitkar, Nora
    Gurung, Radha
    Kumar, Raj K. C.
    Karki, Sanjit
    Shrestha, Roshan
    Rajbhandari, Piyush
    Thapa, Raj K.
    Poudyal, Buddhi
    Acharya, Paras
    Roberts, David J.
    Hayes, Bruce
    Zimmerman, Mark
    Basnyat, Buddha
    BRITISH JOURNAL OF HAEMATOLOGY, 2017, 177 (06) : 1000 - 1007
  • [28] Allosteric BCR-ABL inhibitors in Philadelphia chromosome-positive acute lymphoblastic leukemia: novel opportunities for drug combinations to overcome resistance
    Hantschel, Oliver
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2012, 97 (02): : 157 - 159
  • [29] Prospective monitoring of BCR-ABL1 transcript levels in patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia undergoing imatinib-combined chemotherapy
    Yanada, Masamitsu
    Sugiura, Isamu
    Takeuchi, Jin
    Akiyama, Hideki
    Maruta, Atsuo
    Ueda, Yasunori
    Usui, Noriko
    Yagasaki, Fumiharu
    Yujiri, Toshiaki
    Takeuchi, Makoto
    Nishii, Kazuhiro
    Kimura, Yukihiko
    Miyawaki, Shuichi
    Narimatsu, Hiroto
    Miyazaki, Yasushi
    Ohtake, Shigeki
    Jinnai, Itsuro
    Matsuo, Keitaro
    Naoe, Tomoki
    Ohno, Ryuzo
    BRITISH JOURNAL OF HAEMATOLOGY, 2008, 143 (04) : 503 - 510
  • [30] AMN107, novel aminopyrimidine inhibitor of Bcr-Abl, is significantly more potent than imatinib mesylate against Philadelphia chromosome positive acute lymphoblastic leukemia cells.
    Golemovic, M
    Beran, M
    Giles, F
    Manshouri, T
    Thomas, D
    Cortes, J
    Manley, P
    Alland, L
    Rae, P
    Dugan, M
    Estrov, Z
    Arlinghaus, RB
    Kantarjian, H
    Verstovsek, S
    BLOOD, 2004, 104 (11) : 748A - 748A
12345